Long-acting insulin analogues in the treatment of type 1 and type 2 diabetes;Langwirkende insulinanaloga in der therapie des diabetes mellitus typ 1 und typ 2

Diabetes und Stoffwechsel

Volumn 14, Issue 6, 2005, Pages 375-382

  Tschritter, Otto ^a   Fritsche, Andreas ^a   Gallwitz, Baptist ^a   Häring, Hans Ulrich ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Evidence based medicine; Hypoglycaemia; Insulin analogues; Insulin therapy; Type 1 diabetes; Type 2 diabetes

Indexed keywords

INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; PROTAMINE;

ARTICLE; CLINICAL TRIAL; EVIDENCE BASED MEDICINE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; SYSTEMATIC REVIEW;

EID: 33748920657     PISSN: 09420037     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Bilo HJ, Heine RJ, Sikkenk AC, van der MJ, Van der Veen EA (1987) Absorption kinetics and action profiles of intermediate acting human insulins. Diabetes Res 4: 39-43
2. Lindstrom T, Olsson PO, Arnqvist HJ (2000) The use of human ultralente is limited by great intraindividual variability in overnight plasma insulin profiles. Scand J Clin Lab Invest 60: 341-347
3. R Development Core Team. R: A language and environment for statistical computing. 2005. Vienna, Austria, R Foundation for Statistical Computing. (www.R-project.org)
4. Schwarzer, G. meta: Meta-Analysis. R package version 0.5. 2005. (www.R-project.org)
5. Fleiss JL (1993) The statistical basis of meta-analysis. Stat Methods Med Res 2: 121-145
6. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188
7. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101
8. Egger M, Davey SG, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634
9. Fulcher GR, Gilbert RE, Yue DK (2005) Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Intern Med J 35: 536-542
10. Home PD, Rosskamp R, Forjanic-Klapproth J, Dressier A (2005) A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes. Diabetes Metab Res Rev 21: 545-553
11. Murphy NP, Keane SM, Ong KK, Ford-Adams M, Edge JA, Acerini CL, Dunger DB (2003) Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 26: 799-804
12. Pieber TR, Eugene-Jolchine I, Derobert E (2000) Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes. Diabetes Care 23: 157-162
13. Porcellati F, Rossetti P, Pampanelli S, Fanelli CG, Torlone E, Scionti L, Perriello G, Bolli GB (2004) Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin. Diabet Med 21: 1213-1220
14. Raskin P, Klaff L, Bergenstal R, Halle JP, Donley D, Mecca T (2000) A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 23: 1666-1671
15. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA (2000) Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 23: 639-643
16. Rossetti P, Pampanelli S, Fanelli C, Porcellati F, Costa E, Torlone E, Scionti L, Bolli GB (2003) Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care 26: 1490-1496
17. Schober E, Schoenle E, Van Dyk J, Wernicke-Panten K (2002) Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 15: 369-376
18. HOE 901/2004 Study Investigators Group (2003) Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients. Diabet Med 20: 545-551
19. Fonseca V, Bell DS, Berger S, Thomson S, Mecca TE (2004) A comparison of bedtime insulin glargine with bedtime neutral protamine hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. Am J Med Sci 328:274-280
20. Fritsche A, Schweitzer MA, Haring HU (2003) Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 138: 952-959
21. Massi BM, Humburg E, Dressler A, Ziemen M (2003) A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 35: 189-196
22. Riddle MC, Rosenstock J, Gerich J (2003) The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26: 3080-3086
23. Rosenstock J, Schwartz SL, Clark CM, Jr., Park GD, Donley DW, Edwards MB (2001) Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24: 631-636
24. Yki-Jarvinen H, Dressler A, Ziemen M (2000) Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 23: 1130-1136
25. Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A (2005) Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 28: 950-955
26. Roberts D, Van Wallegham N, Chang H, Pohula W, Cheang M, Moffatt M, Taback S (2005) Glargine versus other basal insulins (NPH, Lente, or Ultralente) for the treatment of type 1 diabetes mellitus. (Protocol). Cochrane Database Syst Rev 2: CD005271
27. Kudva YC, Basu A, Jenkins GD, Pons GM, Quandt LL, Gebel JA, Vogelsang DA, Smith SA, Rizza RA, Isley WL (2005) Randomized controlled clinical trial of glargine versus ultralente insulin in the treatment of type 1 diabetes. Diabetes Care 28: 10-14
28. DeLeeuw I, Vague P, Selam JL, Skeie S, Lang H, Draeger E, Elte JW (2005) Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 7: 73-82
29. Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M (2001) Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care 24: 296-301
30. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA (2004) Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 47: 622-629
31. Home P, Hartley P, Russell-Jones D, Hanaire-Broutin H, Heeg JE, Abrams P, Landin-Olsson M, Hylleberg B, Lang H, Draeger E (2004) Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 27:1081-1087
32. Kolendorf K, Pavlic-Renar I, Santeusiano F, Philotheou A, Gall MA, Heller S (2005): Insulin detemir is associated with lower risk of hypoglycemia compared to NPH insulin in people with type 1 diabetes. Diabetes 53:A130(Abstract)
33. Pieber TR, Draeger E, Kristensen A, Grill V (2005) Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet Med 22: 850-857
34. Robertson K, Schönle E, Gucev Z, Mordhorst L, Tamer SC, Gall MA, Ludvigsson J (2005): Vorteile von Insulindecemir gegenüber NPH-Insulin bei Kindern und Jugendlichen mit Typ-1-Diabetes: Niedrigere und besser reproduzierbare Nüchtern-Plasmaglukose und geringeres nächtliches Hypoglykämierisiko. Diab.Stoffw. 14:88(Abstract)
35. Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bounder J (2004) Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther 26: 724-736
36. Vague P, Selam JL, Skeie S, De L, I, Elte JW, Haahr H, Kristensen A, Draeger E (2003) Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basalbolus regimen with premeal insulin aspart. Diabetes Care 26: 590-596
37. Standl E, Lang H, Roberts A (2004) The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes. Diabetes Technol Ther 6: 579-588
38. Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W (2005) Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 7: 56-64
39. Hermansen K, Derezinski T, Kim H, Gall MA (2004): Treatment with insulin detemir in combination with oral agents is associated with less risk of hypoglycemia and less weight gain than NPH insulin at comparable levels of glycaemic improvement in people with type 2 diabetes. Diabetologia 47: A273(Abstract)
40. Raslova K, Bogoev M, Raz I, Leth G, Gall MA, Hancu N (2004) Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 66: 193-201